retatrutide ly3437943 parkinson's disease clinical trial (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Results Retatrutide Delivers Up to 22.6%

Not everyone who uses a GLP-1 will benefit from or be successful with the therapy, so covering GLP-1s across the board is too costly and would mean higher premiums for everyone

Obese adults, individuals with type 2 diabetes, and MASLD may derive the most advantage

As cardiovascular risk climbs after menopause, we know that when we lose our estrogen, our risk for cardiovascular events goes up, up, up

By the first quarter of 2026, tirzepatide had become the most frequently prescribed agent at roughly 4,700 prescriptions per 100,000 patients, and semaglutide had grown to around 3,900 per 100,000

Best blood test for: Quick checks: Core Health Blood Test Weight loss checks: Weight Loss Blood Test In-depth checks: Advanced Well Woman Blood Test or Advanced Well Man Blood Test GLP-1 injection checks: Weight Loss Injection (GLP-1) Monitoring Blood Test References Geng J, Ni Q, Sun W, Li L, Feng X